PBM Complacency — Sets Stage for Disruption

Until recently, PBMs have had little to no competition in their marketplace, with the top six controlling 95% of the market. CVS Health (NYSE: CVS), Cigna (NYSE: CI), United Health Group (NYSE: UNH), Elevance Health (NYSE: ELV), Humana (NYSE: HUM), and Centene Corp. (NYSE: CNC) essentially comprises the PBM market. They were happy to keep boosting their bottom line through pricing spreads and lucrative rebate deals with big pharma while stifling competition.

The way they accomplished this was by leveraging their market dominance to dictate health insurance plans' drug formularies, demanding high rebates from drug manufacturers in exchange for excluding those drug manufacturers' competitors with cheaper options. PBMs further stifle competition through vertical integration, owning their own pharmacies to steer patients away from independent pharmacies, and using spread pricing (what they charge health plans minus what they pay the pharmacy) to increase costs. In this way, they abused the system. In fact, it has been estimated that $330B+ in annual rebates are siphoned by PBMs rather than being passed to payers (like a health insurance company) or to patients.

Their business model was an iceberg with additional hidden revenue streams, and there was no incentive for them to change until their transparency was challenged by the Consolidated Appropriations Act of 2026 (CAA 2026).

PBMs dipping their hand into consumers' pockets and taking part of the rebates offered by drug makers was pretty much outlawed. The effect of this legislation melted away the profitability of the PBMs and left them with just the administration fee for managing and auditing the prescription. The admin fee was almost a loss leader in their business. Only 20% of their total profits came from administration fees, so investing in technology and data were just "nice-to-have" initiatives. There's a tectonic shift in thinking because now these PBMs have to play catch-up and create a platform technology that bundles wholesale distribution, logistics, data, and auditing software. When 80% of profitability is cast aside by legislation, it's evident that there is enormous demand for a solution that is needed, and fast. Wellgistics has positioned itself as one of these platforms that not only does the traditional wholesale business, but couples it with AI dispensing optimization (EinsteinRx) delivered to the home or pharmacy. They also have the flexibility of incorporating blockchain‑enabled smart contracts (PharmacyChain) targeting the independent pharmacy channel, ensuring the audit requirement and payment of the transaction.

The Evolution of Wellgistics

Wellgistics started as a pharmaceutical wholesaler with a Florida state footprint and focused on serving independent pharmacies, clinics, and healthcare providers. The company expanded to serve customers nationwide under their 50-state FDA-licences. They also maintain certification as a National Association of Boards of Pharmacy (NABP) member which bridges the gap between small to medium sized drug manufacturers and independent retail pharmacies. Then they acquired a delivery platform company that had a white label app for smaller pharmacies. All these elements were eventually rolled up into the public company it is today.

• Wholesale (200 manufacturers in network)
• 3rd Party Logistics (warehouse, inventory, pick-pack, cold chain)
• Technology and Services (prescription routing, prior authorizations, copays, referrals)
• Pharmacy Distribution (6,500 independent specialty pharmacies)
• EinsteinRX
• PharmacyChain

Competitive Positioning and Moat

WGRX isn't taking on the entire PBM market. They have a clear niche of improving the economics of independent pharmacies, clinics, providers that need high‑touch service versus pure scale. What makes them attractive to the independent pharmacies is their nationwide footprint. They are licensed in all 50 states and have NABP accreditation. They also have the option to ship out via mail using their 3rd party logistics platform or pharmacy, while in the background their AI platform optimizes the prescription for profitability. They have over 200 manufacturer relationships which allows them to leverage their buying power as a collective instead of as an individual pharmacy.

WGRX has also embraced technology to create efficiencies in prescription management and has 2 platforms EinsteinRX and PharmacyChain versus the typical PBM filling prescriptions via the same methodology they have been using for the past decade. By far the biggest competitive advantage the company has after Trump's shake up are the patents to put prescriptions on the blockchain and paid out under smart contracts. This is the nail in PBM's proverbial coffin because blockchain is the ideal solution for managing prescriptions and all roads lead back to WGRX and DVLT.

Fallout in the PBM Market

Politics had a huge impact on the PBMs and the stocks started to slide in December 2024 after President Trump planned to "knock out" the "horrible middlemen" that hike drug costs. This was followed by executive action on drug pricing in July 2025 whereby the president cut out the middleman roles. Over the span of one year from July 2024 to July 2025 the top 5 PBMs lost 5 years of gains while the S&P was up over 100%. An opportunity was created in the wake of this structural destruction of the PBM market, and its massive.

Despite the carnage, analysts estimate the market at almost $900 billion in 2026 and growing to $1.78 trillion by 2034. The bottom line is that patients still need their prescription drugs processed and that is the function of the PBM. Analysts have chopped estimates and the stocks in this sector have cratered because they understand that PBMs have inefficient processing and auditing capabilities. Bain & Company cited the GLP-1 drugs, a major driver of prescriptions, has complicated the reimbursement process. The trends are showing that retail pharmacies are sourcing their GLP-1s at a higher rate than they are being reimbursed, resulting in a loss on the prescription. PBM's need to figure this out and fast, and therein lies the opportunity for a technological solution to digitize prescriptions.

Seizing Opportunity

Wellgistics has had a lot of news that positions themselves as a disruptor in the space. Their EinsteinRx platform uses AI to figure out if its more advantageous to ship to the home versus pick it up in a pharmacy. This optimization creates efficiency in their pharmacy ecosystem. Their goal is to get to a run rate of over 500 pharmacy signups per month by the end of 2026. Management feels that EinsteinRx has the capability to not only pick the optimal drugs and ship them the best way but also recommend better combinations to treat conditions which result in better patient outcomes. There is also a sweet spot in their business when it comes to targeted therapies, like SGLT‑2 for diabetes, not to mention GLP‑1/weight‑loss drugs. Their platform ensures optimal reimbursement before processing otherwise it will be rejected.

WGRX is also developing PharmacyChain, which is essentially a smart‑contract platform that uses licensed technology from DataVault AI (NASDAQ: DVLT), including quantum key encryption to satisfy HIPAA compliance. Smart contracts automatically verify and process claims in 60 days without manual audits. The Trump administration's cumbersome audit requirements for prescriptions are automated versus manual like the rest of the PBM market. The result is a blockchain solution that provides a permanent, tamper-proof audit trail on every single transaction.

Together, EinsteinRx and PharmacyChain are expected to improve data security, automate complex contracts, and form the basis of new payment programs between manufacturers, pharmacies and payers that's transparent from the pill factory to the patients mouth.

Taming the Wild West of GLP-1s

GLP-1s are a huge revenue driver for independent pharmacies but the pitfall is that they can fill the prescription, but they don't really know upfront if they are going to get enough reimbursement to cover their costs. This adds an element of risk to the business and results in them stocking less inventory of these highly demanded drugs. For pharmacies in the WGRX ecosystem they have access to EinsteinRX and PharmacyChain and can verify profitable reimbursement levels up front via smart contracts ensuring that if the pharmacy fills the prescription they are going to maintain a profit without the need for manual audits. Utilizing this process WGRX could boost approval rates which leads to more business and more economies of scale by getting a sliver of the $53 billion GLP-1 market. Additional initiatives include GLP‑1 companion medical foods through Tollo Health and offerings around Long COVID and related conditions, supported by partnerships with NFL Alumni Health for community outreach.

The network is already being used to commercialize Brenzavvy, a type 2 diabetes drug that Wellgistics began launching across its independent pharmacy base in December 2025. Management ties this effort to a large addressable market: roughly 33 million U.S. adults with type 2 diabetes and SGLT‑2 class sales estimated at 16.8 billion dollars in 2024 with projections nearing 28.9 billion dollars by 2033.

Financial Snapshot

Wellgistics Health has suffered along with the rest of the PBMs and is trading at a $15 million market cap. The shares sit near their 52‑week low of $.19 after hitting a 52-week high of $7.00. There is a lot of volatility in this name as well as risk. The key metric is their cash on hand. They had $4.2 million in cash at the end of Q3 which was up over 900% from the prior quarter. This demonstrates their ability to raise capital and gives them enough runway to execute their plan to drive their growth initiatives with their technology platform expansion. On January 6, 2026 they boosted their cash position by $6.5 million by issuing $8.1 mil in convertible notes with a 6 month maturity.

Their inventory levels are relatively high in comparison to sales, but it's likely needed to fuel their growth. During the quarter inventory dropped 17% to $7.5 million from Q2's $9.0 million, but this appears to be part of management's discipline in containing costs and improving the balance sheet. In August they started stabilizing the operation to support growth initiatives and the CFO stated:

During the last quarter Gross margins got better, hitting 7.7% in Q3. That's up from 6.5% in Q2 and 6.4% in Q1. Management's strategic shift toward higher gross margin products generated $3.0 million in revenues resulting in $231K in gross profit. The markets they are targeting should start to show revenue growth within the coming quarter. They had a large loss of $31.5 million but that was primarily due to stock based compensation.

Risks and Downside Scenarios

When dealing with prescriptions, the regulatory and compliance risks are the black swans of the industry. WGRX could face disruptions from the Drug Supply Chain Security Act (DSCSA), state board actions, or from accreditation requirements. Their business is heavily dependent on inventory and the loss of a key manufacturer to supply them or the inability to get competitive pricing due to the rising purchasing power of large PBMs could negatively hurt operations. There is also a lot of execution risk because they are trying to scale a vertically integrated operation that has logistics, warehousing, and regulatory compliance.

Although they are a NASDAQ stock, their liquidity is not as great as larger healthcare companies which means investors need to feel comfortable with the volatility and lack of liquidity in small capitalization companies.

Growth Drivers and Potential Catalysts

They have a very disruptive platform technology and almost all the PBMs need it but none are going to buy until the platform has been tested and that is where WGRX and its pharmacies come into view. If WGRX proves the cost saving, the logistical savings, the ability to effect payment through smart contracts, their business is going to grow exponentially. At that time they could see sit downs with a number of the Pharmacy Benefit Managers to explore licensing or acquiring the technology.

Catalysts to watch out for:

Building out the Platform — Their goal is to onboard up to 500 pharmacies per month onto the EinsteinRx platform which looks a lot like a SaaS revenue stream on top of their existing distribution business.

New therapy expansion — Beyond the generics they have a new market selling Brenzavvy and GLP‑1 related products. They are also looking to expand into mental health, sleep apnea, pain and Long COVID. This increase in script volume broadens the appeal for distribution partners.

Monetizing Smart Contracts — If the rollout of PharmacyChain and DataVault AI gain traction in the market by automating the payment of scripts and the optimization of delivery then costs will go down. Through technology the digitization of scripts could be a big boon for revenue growth.

Partnership Deals — Given how specialized the company is there is a credible path to finding a PBM partner or a licensing deal with multiple PBMs. The only caveat being that WGRX will need to prove its model at scale.

Investment View

There is a huge opportunity in the PBM market for disruptors, and the low market cap of $15 million coupled with their smart-contract technology makes WGRX a value play. Wellgistics with their disruptive technology offers investors a speculative way to gain exposure to the growth independent pharmacies are seeing from the rapidly expanding GLP-1 market. WGRX has a killer app capable of digitizing prescriptions and smart contracts that can automatically audit and payout participants. The company is executing on its plan and about to roll out an exciting line of high margin products that include weight loss options through its network of 6,500 pharmacies utilizing its disruptive platform technology solutions. If they get traction and prove that they can use technology to upgrade the existing way prescriptions are currently handled, they could become the "must have solutions" that larger PBMs need in order to lower their cost structure. It's worth noting that if WGRX succeeds in proving their model in the near future, their partner DataVault (NASDAQ: DVLT) has the patented protection they need to bring the top 3 PBMs to the negotiating table.

The road to success isn't adorned exclusively with roses because there are some thorns in the form of risks. It's a highly volatile and speculative investment and their success depends on their continued ability to raise capital or quickly execute their business plan which means a long time horizon may be warranted. For other investors Wellgistics may warrant putting it on their watch list as a high‑risk/high‑reward small‑cap in the evolving independent pharmacy and healthcare technology space. Once the company meets some of its milestones, investors may find it appropriate to position based on sales metrics, cost containment, and partnership announcements.